Why the study?
Does YM866 improve recanalization compared to tPA in a canine model of femoral arterial thrombosis?
Population
Canine model of copper-coil-induced femoral arterial thrombosis
Comparison
YM866 administered by intravenous bolus… vs Tissue-type plasminogen activator administered…
Design
Preclinical
Authors
Loading...
Bolus YM866 matches tPA infusion efficacy in canine thrombosis; leaves open translation to human thrombolysis trials.
Does YM866 improve recanalization compared to tPA in a canine model of femoral arterial thrombosis?
A mutant tPA (YM866) administered as an intravenous bolus at a lower dose provides equivalent thrombolytic efficacy to standard tPA infusion in a canine thrombosis model.
Kawasaki et al. (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: